Brown Brothers Harriman & Co’s TScan Therapeutics TCRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Hold	143,051	–	–	﹤0.01%	930
2026 Q1	$144K	Hold	143,051	–	–	﹤0.01%	865
2025 Q4	$143K	Hold	143,051	–	–	﹤0.01%	834
2025 Q3	$260K	Hold	143,051	–	–	﹤0.01%	627
2025 Q2	$207K	Hold	143,051	–	–	﹤0.01%	627
2025 Q1	$197K	Hold	143,051	–	–	﹤0.01%	560
2024 Q4	$435K	Hold	143,051	–	–	﹤0.01%	432
2024 Q3	$712K	Buy	143,051 +67,027	+88%	+$404K	﹤0.01%	343
2024 Q2	$445K	Buy	+76,024	New	+$599K	﹤0.01%	395

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Brown Brothers Harriman & Co's TCRX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 143,051 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #930.

Brown Brothers Harriman & Co first reported a position in TCRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $712K in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Brown Brothers Harriman & Co held 143,051 shares of TScan Therapeutics worth $140K as of Q2 2026.
Brown Brothers Harriman & Co left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #930 holding.
Brown Brothers Harriman & Co first reported a position in TScan Therapeutics in Q2 2024 and has held it in 9 quarters since.
Brown Brothers Harriman & Co's TScan Therapeutics position peaked at $712K in Q3 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.